Scarica l'app Stockscreener
75.25
1.06%
-0.81
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BBIO Giù?
Forum
Previsione
Precedente Chiudi:
$76.06
Aprire:
$77.55
Volume 24 ore:
2.82M
Relative Volume:
1.12
Capitalizzazione di mercato:
$14.42B
Reddito:
$353.78M
Utile/perdita netta:
$-805.69M
Rapporto P/E:
-17.97
EPS:
-4.1869
Flusso di cassa netto:
$-597.61M
1 W Prestazione:
+10.58%
1M Prestazione:
-4.88%
6M Prestazione:
+49.36%
1 anno Prestazione:
+138.43%
Intervallo 1D:
$72.82
$77.78
Intervallo di 1 settimana:
$67.82
$84.94
Portata 52W:
$28.32
$84.94
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Nome
Bridgebio Pharma Inc
Settore
Industria
Telefono
(650) 391-9740
Indirizzo
3160 PORTER DR., PALO ALTO, CA
Compare BBIO vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
75.25 | 14.58B | 353.78M | -805.69M | -597.61M | -4.1869 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2026-01-06 | Iniziato | Morgan Stanley | Overweight |
| 2025-12-11 | Iniziato | Bernstein | Outperform |
| 2025-07-30 | Ripresa | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-14 | Iniziato | Jefferies | Buy |
| 2025-07-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-06-17 | Iniziato | Wolfe Research | Outperform |
| 2025-03-31 | Iniziato | Redburn Atlantic | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-03 | Iniziato | Oppenheimer | Perform |
| 2024-09-04 | Iniziato | Piper Sandler | Overweight |
| 2024-03-21 | Ripresa | Raymond James | Outperform |
| 2024-01-31 | Iniziato | BMO Capital Markets | Market Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-11-07 | Iniziato | Citigroup | Buy |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Downgrade | Jefferies | Buy → Hold |
| 2023-04-19 | Iniziato | Evercore ISI | Outperform |
| 2023-02-06 | Iniziato | Cowen | Outperform |
| 2021-12-27 | Reiterato | Mizuho | Buy |
| 2021-12-27 | Reiterato | SVB Leerink | Outperform |
| 2021-09-10 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-03-22 | Reiterato | Goldman | Buy |
| 2021-02-22 | Ripresa | JP Morgan | Overweight |
| 2021-02-09 | Ripresa | Goldman | Buy |
| 2021-01-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-10 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-25 | Iniziato | BofA/Merrill | Neutral |
| 2020-05-19 | Iniziato | BTIG Research | Buy |
| 2020-04-13 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-19 | Iniziato | Mizuho | Buy |
| 2019-07-26 | Iniziato | Raymond James | Outperform |
| 2019-07-22 | Iniziato | BMO Capital Markets | Outperform |
| 2019-07-22 | Iniziato | Goldman | Buy |
| 2019-07-22 | Iniziato | JP Morgan | Overweight |
| 2019-07-22 | Iniziato | Jefferies | Buy |
| 2019-07-22 | Iniziato | Piper Jaffray | Overweight |
| 2019-07-22 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Bridgebio Pharma Inc Borsa (BBIO) Ultime notizie
Is BridgeBio Pharma Inc. a stock for growth or value investorsJuly 2025 Price Swings & Stepwise Trade Signal Guides - mfd.ru
Why BridgeBio Pharma (BBIO) Is Up 10.6% After Breakthrough Phase 3 Infigratinib Data In Achondroplasia - Yahoo Finance
BridgeBio Pharma, DoorDash, Nvidia, Rio Tinto: What brokers said this week - Proactive financial news
Is BridgeBio Pharma Inc. a speculative investment2025 Top Decliners & AI Driven Stock Movement Reports - mfd.ru
BridgeBio Pharma (NASDAQ:BBIO) Given New $83.00 Price Target at Oppenheimer - MarketBeat
BBIO: Oppenheimer Raises Price Target for BridgeBio Pharma | BBIO Stock News - GuruFocus
BridgeBio's Impressive Phase 3 Infigratinib Data Adds Competitive Pressure to BioMarin's Voxzogo - Morningstar
Oppenheimer Adjusts BridgeBio Pharma Price Target to $83 From $81, Maintains Outperform Rating - marketscreener.com
BBIO: Wells Fargo Raises Price Target to $98 While Maintaining 'Overweight' Rating | BBIO Stock News - GuruFocus
Wells Fargo & Company Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price - MarketBeat
BridgeBio looks to challenge BioMarin in dwarfism market on Phase III win - Clinical Trials Arena
BridgeBio Pharma stock hits all-time high at 84.51 USD By Investing.com - Investing.com South Africa
Jefferies Maintains Buy on BBIO BridgeBio Pharma, Inc. Feb 2026 - Meyka
Allspring Growth Fund Q4 2025 Fund Performers And Detractors - Seeking Alpha
BridgeBio Confident Infigratinib Can Steal Achondroplasia Market Share - Citeline News & Insights
BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar Sells 40,000 Shares - MarketBeat
Dwarfism golden gate? Bridgebio’s infigratinib phase III hits - BioWorld MedTech
BridgeBio Announces Positive Phase 3 Achondroplasia Trial Results - TipRanks
Dwarfism meds 'miraculously' took kids who started at a low growth baseline to typical height velocity: BridgeBio Pharma CEO - Fox Business
BridgeBio Pharma shares rise on ‘compelling’ Phase 3 trial results for achondroplasia drug - Proactive financial news
BridgeBio reports positive phase 3 topline results for oral infigratinib - marketscreener.com
BridgeBio Stands Tall as Phase 3 Data Put Dwarfism Drug on Track for FDA Filing - MedCity News
BridgeBio Pharma (NASDAQ:BBIO) Reaches New 52-Week HighHere's What Happened - MarketBeat
BridgeBio's oral drug improves growth in children with dwarfism in late-stage study - marketscreener.com
BBIO Stock Surges 17% Pre-Market Today – What’s Fueling The Rally? - Stocktwits
BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 - Bitget
BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 - Benzinga
BridgeBio (BBIO) Surges on Positive Phase 3 Results for Infigrat - GuruFocus
BridgeBio gains on phase 3 dwarfism data - pharmaphorum
Positive Phase III top-line results for BridgeBio’s oral infigratinib - The Pharma Letter
BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis - BioPharma Dive
BridgeBio Pharma (BBIO) May Report Negative Earnings: Know the Trend Ahead of Q4 Release - Finviz
BridgeBio Pharma stock price target raised to $89 at Raymond James on positive trial data - Investing.com Canada
BridgeBio Pharma stock hits all-time high at 84.51 USD - Investing.com
BridgeBio Pharma Touts Strong Phase 3 PROPEL-3 Data for Oral Infigratinib in Achondroplasia - MarketBeat
BridgeBio posts trial win for dwarfism drug (BBIO:NASDAQ) - Seeking Alpha
BioMarin, Ascendis stocks fall after BridgeBio’s positive achondroplasia data By Investing.com - Investing.com Canada
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia - The Manila Times
BridgeBio stock jumps after positive Phase 3 results for achondroplasia drug - Investing.com Canada
BridgeBio Pharma Reports Positive Topline Results from PROPEL 3 Study of Oral Infigratinib in Children with Achondroplasia - Quiver Quantitative
BBIO: Oral infigratinib delivers significant growth and proportionality benefits in achondroplasia - TradingView
BridgeBio's oral drug boosts growth in children with dwarfism in late-stage trial - Reuters
Oral drug helps achondroplasia patients grow faster, improve body proportions - Stock Titan
How BridgeBio Pharma Inc. stock reacts to global recession fearsJuly 2025 Earnings & Fast Gaining Stock Reports - mfd.ru
BridgeBio Pharma (BBIO) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Why (BBIO) Price Action Is Critical for Tactical Trading - Stock Traders Daily
What is BridgeBio Pharma Inc.’s book value per shareWeekly Profit Recap & Verified Chart Pattern Trade Signals - mfd.ru
Candriam S.C.A. Invests $7.74 Million in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma supports LGMD Family Guide distribution at conference - Traders Union
Targets Report: What are the analyst revisions for NSTSIs BridgeBio Pharma Inc stock a good investment in YEARJuly 2025 Decliners & Fast Gain Stock Trading Tips - baoquankhu1.vn
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Bridgebio Pharma Inc Azioni (BBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Bridgebio Pharma Inc Azioni (BBIO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kumar Neil | Chief Executive Officer |
Feb 11 '26 |
Sale |
71.78 |
40,000 |
2,871,087 |
675,686 |
| Kumar Neil | Chief Executive Officer |
Jan 09 '26 |
Sale |
77.11 |
40,000 |
3,084,313 |
715,686 |
| Kumar Neil | Chief Executive Officer |
Jan 08 '26 |
Sale |
73.97 |
40,000 |
2,958,855 |
735,686 |
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):